Trial · NCT06044337
Registered outcomes36
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 36
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Up to 232 weeks | |
| Secondary | Percentage of Participants who Achieve a Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity Score (CLASI)-70 Response, Defined as a 70% Decrease in CLASI-A Score From the Baseline Value (Parent Study [NCT05531565]) | Up to 232 weeks | |
| Secondary | Percentage of Participants who Achieve a CLASI-50 Response, Defined as a 50% Decrease in CLASI-A Score From the Baseline Value (Parent Study [NCT05531565]) | Up to 232 weeks | |
| Secondary | Percentage of Participants who Achieve a CLASI-90 Response, Defined as a 90% Decrease in CLASI-A Score From the Baseline Value (Parent Study [NCT05531565]) | Up to 232 weeks | |
| Secondary | Percentage of Participants who Achieve a Cutaneous Lupus Activity of Physician's Global Assessment-Revised (CLA-IGA-R) Erythema Score of 0 or 1 | Up to 232 weeks | |
| Secondary | Percentage of Participants who Achieve a CLA-IGA-R Other Morphologic Characteristics (OMC) Score of 0 | Up to 232 weeks | |
| Secondary | Percentage of Participants With a CLASI-70 Response Among CLASI-70 Responders at Long-Term Extension (LTE) Baseline | Day 1 (LTE Baseline) up to 232 weeks | |
| Secondary | Percentage of Participants With a CLASI-50 Response Among CLASI-50 Responders at LTE Baseline | Day 1 (LTE Baseline) up to 232 weeks | |
| Secondary | Percentage of Participants With a CLASI-90 Response Among CLASI-90 Responders at LTE Baseline | Day 1 (LTE Baseline) up to 232 weeks | |
| Secondary | Percentage of Participants With a CLA-IGA-R Erythema Score of 0 or 1 Among Participants With a CLA-IGA-R Erythema Score of 0 or 1 at LTE Baseline | Day 1 (LTE Baseline) up to 232 weeks | |
| Secondary | Percentage of Participants With CLA-IGA-R OMC Score of 0 or 1 and at Least 1 Level of Improvement From Baseline Value(Parent Study) Among Participants With CLA IGA R OMC Score of 0 or 1 and at Least 1 Level Improvement From Baseline Value(Parent Study) | Day 1 (LTE Baseline) up to 232 weeks | |
| Secondary | Percentage of Participants With a CLASI-70 Response Among CLASI-50 Responders at LTE Baseline | Day 1 (LTE Baseline) up to 232 weeks | |
| Secondary | Percentage of Participants With Loss of Response, Defined as an Increase of ≥ 7 Points in CLASI-A Total Score From Baseline | Day 1 (LTE Baseline) up to 232 weeks | |
| Secondary | Percentage of Participants who Achieve a CLASI A Score of 0 to 3 | Up to 232 weeks | |
| Secondary | Percentage of Participants who Achieve a CLASI-A Score of 0 to 5 | Up to 232 weeks | |
| Secondary | Percentage of Participants With a CLASI-A 0 to 3 Response Among CLASI-A 0 to 3 Responders at LTE Baseline | Day 1 (LTE Baseline) up to 232 weeks | |
| Secondary | Absolute Change From Baseline in CLASI-A Score of Parent Study (NCT05531565) to Week 208 | Day 1 (Baseline of Parent study) up to 208 weeks | |
| Secondary | Percent Change From Baseline in CLASI-A Score of Parent Study (NCT05531565) to Week 208 | Day 1 (Baseline of Parent study) up to 208 weeks | |
| Secondary | Absolute Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index Damage (CLASI-D) Score From Baseline Value (Parent Study [NCT05531565]) to Week 208 | Up to 208 weeks | |
| Secondary | Percent Change in CLASI-D Score From Baseline Value (Parent Study [NCT05531565]) to Week 208 | Up to 208 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06044337/registered